Cost Considerations for Talquetamab in Multiple Myeloma Treatment

Introduction to Talquetamab and Its Costs

• The estimated cost of one vial of talquetamab ranges between 10,000 and 12,000 euros, based on prices of similar oncologic and bispecific drugs recently approved 1

Cost Comparison with Other Oncologic Drugs

• Monoclonal antibodies like trastuzumab deruxtecan cost approximately $11,158 per cycle, as reported by the Journal of Clinical Oncology in 2022 1
• Biological drugs for multiple myeloma have costs ranging from $10,000 to $15,000 per treatment cycle 2
• The cost per cycle of innovative oncologic drugs varies significantly, with some exceeding $20,000, according to the Journal of Clinical Oncology in 2021 and 2022 1, 2

Factors Influencing Talquetamab Costs

• The dosage, formulation, duration of treatment, and production costs are factors that influence the cost of talquetamab, although specific details on these aspects are not provided in the given context 1, 2

Efficacy and Cost Justification

• While specific efficacy data for talquetamab is not provided in the context, its high therapeutic value for patients with relapsed or refractory multiple myeloma who have exhausted standard treatment options can justify its elevated cost, based on the principle that effective treatments may warrant higher costs due to their clinical benefits 1, 2